CTOs on the Move

Dainippon Sumitomo Pharma America Holdings

www.ds-pharma.com

 
Dainippon Sumitomo Pharma America Holdings is a Fort Lee, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million
  • www.ds-pharma.com
  • 1 Bridge Plz N Ste 510
    Fort Lee, NJ USA 07024
  • Phone: 201.592.2050

Executives

Name Title Contact Details

Similar Companies

Cycle Pharmaceuticals

WHAT WE DO Cycle Pharmaceuticals is a global, privately-owned and patient-dedicated biotechnology company headquartered in Cambridge in the UK. Our mission is to utilise the latest pharmaceutical technologies to deliver superior drug treatments to b...

Neopharm Labs

As a trusted partner to leaders in the pharmaceutical and life sciences industry for over 30 years, we`ve built a reputation for quality, problem‑solving capabilities, and a superior customer experience. We`re proud to play an integral role in bettering the lives of the global community.

New Century INfusion Solutions

New Century INfusion Solutions is a Brea, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Almat Pharmachem

Almat Pharmachem Inc. is a Concord, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Corcept Therapeutics

Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym’s active ingredient, which is in a Phase 1/2 trial in combination with the chemotherapy drug eribulin (Halaven) to treat patients with GR-positive triple-negative breast cancer, a form of cancer with a particularly poor prognosis; and CORT 125134, a proprietary, selective GR antagonist that is in a Phase 1 clinical study to assess its safety, tolerability, and pharmacokinetics in healthy human volunteers. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited and Sygnature Discovery Limited. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.